

Letters

RESEARCH LETTER

Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France

COVID-19 mRNA vaccine immunogenicity and effectiveness are well established in adolescents.¹ However, the effect of vaccination on multisystem inflammatory syndrome in children (MIS-C),² a severe complication associated with SARS-CoV-2,³ has not yet been described. Summer 2021 in France was marked by both a fourth wave of COVID-19 cases due to the Delta variant, with a peak in August 2021, and by the recommendation of the French Public Health Agency to vaccinate children 12 years and older. We estimated the risk of MIS-C among adolescents by COVID-19 vaccination status during September 2021 and October 2021.

Methods | All pediatric patients diagnosed with MIS-C according to World Health Organization criteria and admitted to one of the 41 French pediatric intensive care units (PICUs) between September 1, 2021, to October 31, 2021, were included in this study. In addition, all patients with MIS-C who were not admitted to a PICU and mandatorily reported to the French Public Health Agency⁴ during this period were included.

Data regarding age, sex, admission to a PICU, and vaccination status of patients 12 to 18 years (hereafter referred to as *adolescents*) were recorded.

To account for the increasing number of adolescents vaccinated over time, including during the period in which MIS-C cases were measured, hazard ratios (HRs) of unvaccinated vs vaccinated adolescents with at least 1 dose of vaccine were estimated using Cox proportional hazards model. Given the delays between vaccine injection and immune response and

between SARS-CoV-2 infection and MIS-C onset, 3 sensitivity analyses were performed in which adolescents were considered vaccinated at least 14, at least 28, and at least 42 days after the first vaccine dose. The delay of more than 42 days covers the 28 days between the first and second injection and 2 additional weeks to achieve full immunity. Data describing vaccination status per day are available from <https://solidarites-sante.gouv.fr/grands-dossiers/vaccin-covid-19/article/le-tableau-de-bord-de-la-vaccination>.

All statistical analyses were performed with Stata, version 16.1 (StataCorp), and 2-sided $P < .05$ was considered statistically significant.

This study was approved as a medical registry assessment without a requirement for patient consent by the French Advisory Committee on Information Processing in Health Research.

Results | On June 15, 2021, the beginning of the adolescent COVID-19 vaccination campaign, 2.2% of the 4 989 013 adolescents in France were vaccinated with at least 1 dose and 0.2% were fully vaccinated. On October 31, 2021, vaccination rates reached 76.7% of adolescents having received at least 1 dose and 72.8% being fully vaccinated. Vaccines used were BNT162b2 (Pfizer-BioNTech; >95%), mRNA-1273 (Moderna; <5%), and other COVID-19 vaccines (<1%).

From September 1, 2021, to October 31, 2021, a total of 107 children with MIS-C were hospitalized in France and, among them, 33 (31%) were adolescents eligible for vaccination. Adolescents with MIS-C were a median (IQR) age of 13.7 (12.5-14.9) years, 27 (81%) were male, and 29 (88%) were admitted to a PICU. Among them, 0 had been fully vaccinated, 7 had received 1 dose with a median (IQR) time between vaccine injection and MIS-C onset of 25 (17-37) days, and 26 had not been vaccinated. The HR for MIS-C was 0.09 (95% CI, 0.04-0.21;

Table. Multisystem Inflammatory Syndrome in Children (MIS-C) Risk by COVID-19 Vaccination Status of Adolescents

COVID-19 vaccination status ^a	No. of patients with MIS-C (N = 33)	Hazard ratio (95% CI) ^b	P value
Unvaccinated	26	1 [Reference]	<.001
One dose	7	0.09 (0.04-0.21)	
Sensitivity analysis: fully vaccinated ≥ 14 d after first dose ^c			
Unvaccinated	28	1 [Reference]	<.001
One dose	5	0.07 (0.03-0.18)	
Sensitivity analysis: fully vaccinated ≥ 28 d after first dose ^c			
Unvaccinated	31	1 [Reference]	<.001
One dose	2	0.03 (0.01-0.12)	
Sensitivity analysis: fully vaccinated ≥ 42 d after first dose ^c			
Unvaccinated	31	1 [Reference]	<.001
One dose	2	0.04 (0.01-0.16)	

^a More than 95% of vaccinated adolescents received BNT162b2 (Pfizer-BioNTech), <5% received mRNA-1273 (Moderna), and <1% received other COVID-19 vaccines.

^b Cox proportional hazards regression models were used to calculate hazard ratios, with the number of adolescents vaccinated with at least 1 dose as the exposure and MIS-C as the outcome.

^c Given the delays between vaccine injection and immune response, and between SARS-CoV-2 infection and MIS-C onset, 3 sensitivity analyses were performed in which adolescents were considered vaccinated at least 14, at least 28, and at least 42 days after the first vaccine dose.

$P < .001$) after the first vaccine dose compared with unvaccinated adolescents. Sensitivity analyses showed similar results (Table).

Discussion | Most adolescents with MIS-C for whom vaccination was indicated in France had not been vaccinated. These results suggest that COVID-19 mRNA vaccination was associated with a lower incidence of MIS-C in adolescents. The median of 25 days between single vaccine injection and MIS-C onset compared with a mean 28-day delay between SARS-CoV-2 infection and MIS-C onset⁴ suggests that, in most cases, SARS-CoV-2 infection occurred before or shortly after the vaccine injection, when immune response was incomplete. The absence of MIS-C cases in fully vaccinated children prevented calculation of an HR for this group, but suggests that 2 doses are warranted for efficient protection. The study had limitations, including the low number of patients, use of national data to calculate HR without considering regional variations, and inability to control for individual risks of MIS-C, such as sex, race and ethnicity, and comorbidities.⁵

The association between mRNA vaccination with MIS-C in younger children should be evaluated as vaccines are approved for use in children aged 5 to 11 years. Close monitoring is required given the alert on myocarditis occurring in adolescents after COVID-19 mRNA vaccine.⁶

Michael Levy, MD, PhD
Morgan Recher, MD, PhD
Hervé Hubert, MD, PhD
Etienne Javouhey, MD, PhD
Olivier Fléchelles, MD, PhD
Stéphane Leteurtre, MD, PhD
François Angoulvant, MD, PhD

Author Affiliations: Pediatric Intensive Care Unit, Hôpital Universitaire Robert-Debré, Paris, France (Levy); ULR 2694 - METRICS, Université de Lille, Lille, France (Recher, Hubert, Leteurtre); Pediatric Intensive Care Unit, Hôpital Femme Mère Enfant, Lyon, France (Javouhey); Pediatric Intensive Care Unit, Centre Hospitalier Universitaire de Martinique, Fort-de-France, France (Fléchelles); Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Hôpital Universitaire Robert-Debré, Paris, France (Angoulvant).

Corresponding Author: Michael Levy, MD, PhD, Pediatric Intensive Care Unit, Hôpital Universitaire Robert-Debré, Assistance Publique-Hôpitaux de Paris, 48 boulevard Sérurier, 75019 Paris, France (michael.levy@aphp.fr).

Accepted for Publication: December 8, 2021.

Published Online: December 20, 2021. doi:[10.1001/jama.2021.23262](https://doi.org/10.1001/jama.2021.23262)

Author Contributions: Drs Levy and Angoulvant had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Levy, Recher, Javouhey, Angoulvant.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Levy, Angoulvant.

Critical revision of the manuscript for important intellectual content: Levy, Recher, Hubert, Javouhey, Fléchelles, Leteurtre.

Statistical analysis: Levy, Angoulvant.

Obtained funding: Hubert, Leteurtre.

Administrative, technical, or material support: Recher, Hubert, Javouhey, Leteurtre, Angoulvant.

Supervision: Levy, Javouhey, Angoulvant.

Conflict of Interest Disclosures: Dr Angoulvant reported receiving lecture fees from Pfizer and being the principal investigator of the PANDOR study, which received an unrestricted grant from Pfizer. No other disclosures were reported.

Additional Contributions: We are grateful to Groupe Francophone de Réanimation et d'Urgences Pédiatriques, Santé Publique France, Société Française de Pédiatrie, Groupe de Pédiatrie Générale, Groupe de Pathologie Infectieuse Pédiatrique, Société Française de Cardiologie, Filiale de Cardiologie Pédiatrique et Congénitale, Société Francophone Dédiée à L'étude des Maladies Inflammatoires Pédiatriques, and Filière de Santé des Maladies Auto-immunes et Auto-inflammatoires Rares for their participation in the French COVID-19 Paediatric Inflammation Consortium. We thank Daniel Levy-Bruhl, MD; Denise Antona, MD; and Isabelle Parent-du-Chatelet, MD (Santé Publique France Agence Nationale de Santé Publique, Saint-Maurice); David Skurnik, PhD (INSERM U1151-Equipe 11, Paris); and Naïm Ouldali (Hôpital Universitaire Robert-Debré, Paris) for their advice and all the caregivers who included patients in the study. No compensation was provided to these individuals.

1. Frenck RW Jr, Klein NP, Kitchin N, et al; C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. *N Engl J Med*. 2021;385(3):239-250. doi:[10.1056/NEJMoa2107456](https://doi.org/10.1056/NEJMoa2107456)
2. Feldstein LR, Rose EB, Horwitz SM, et al; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US children and adolescents. *N Engl J Med*. 2020;383(4):334-346. doi:[10.1056/NEJMoa2021680](https://doi.org/10.1056/NEJMoa2021680)
3. Whittaker E, Bamford A, Kenny J, et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. *JAMA*. 2020;324(3):259-269. doi:[10.1001/jama.2020.10369](https://doi.org/10.1001/jama.2020.10369)
4. Belot A, Antona D, Renolleau S, et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. *Euro Surveill*. 2020;25(22):2001010. doi:[10.2807/1560-7917.ES.2020.25.22.2001010](https://doi.org/10.2807/1560-7917.ES.2020.25.22.2001010)
5. Dhar D, Dey T, Samim MM, et al. Systemic inflammatory syndrome in COVID-19-SISCoV study: systematic review and meta-analysis. *Pediatr Res*. Published online May 18, 2021. doi:[10.1038/s41390-021-01545-z](https://doi.org/10.1038/s41390-021-01545-z)
6. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19. *JAMA*. 2021;326(12):1210-1212. doi:[10.1001/jama.2021.13443](https://doi.org/10.1001/jama.2021.13443)